Compare PDSB & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDSB | RFL |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 69.7M |
| IPO Year | 2015 | 2017 |
| Metric | PDSB | RFL |
|---|---|---|
| Price | $1.17 | $1.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 51.2K |
| Earning Date | 05-14-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.16 | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.51 | $1.12 |
| 52 Week High | $1.90 | $3.19 |
| Indicator | PDSB | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 59.53 |
| Support Level | $0.85 | $1.28 |
| Resistance Level | $1.47 | $1.59 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 35.86 | 92.86 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.